Israel Anti-Hypertensive Drugs Market, By Therapeutic Class (Diuretics, ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others), By Type (Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores), By Region, Competition Forecast & Opportunities, 2028

Israel Anti-Hypertensive Drugs Market is expected to grow at an impressive rate during the forecast period 2024-2028. The major factors include increasing prevalence of hypertension due to kidney diseases, diabetes, obstructive sleep apnea, and other cardiovascular diseases due to which the prevalence of hypertension has observed a significant rise over the past few years. Also, some drugs can induce hypertension in patients with other diseases or disorders, which in turn, is expected to promote the growth of the Israel Anti-Hypertensive Drugs market. According to World Health Organization 2021, around 1.13 billion people across the world have hypertension, of which two-third are living in low- and middle-income countries.

Hypertension is a preventable risk factor for atherosclerotic diseases and ischemic heart diseases. This condition is marked by high pressure of blood in the arteries. A number of patients maintain suboptimal blood pressure control, despite the modern and effective antihypertensive drugs. Most hypertensive patients require a combination of antihypertensive agents to prevent heart stroke.

Additionally, rise in awareness related to complications associated with hypertension is a major factor that fuels the growth of Israel anti-hypertensive drugs market. Moreover, the increase in geriatric population and sedentary lifestyle also boosts the growth of the market. However, recent patent expirations are anticipated to hinder the growth of the antihypertensive market. Conversely, rise in research related to antihypertensive drugs is expected to offer lucrative opportunities during the forecast period.

Increasing Prevalence of Hypertension

The increasing prevalence of hypertension is a major health concern across the country. According to recent data, hypertension affects around 25% of the adult population in Israel, with the prevalence increasing with age. One of the main contributing factors to the increasing prevalence of hypertension in Israel is the aging population. As people age, the risk of developing hypertension increases. According to United Nations Economic Commission for Europe, Israel has a rapidly aging population, with around 11% of the population aged 65 and over in 2021, and this demographic shift is expected to continue in the coming years. Israel’s elderly population has some unique characteristics because the country receives a steady stream of immigrants from 119 countries, including many who are Holocaust survivors, representing a wide range of ethnic, economic, health, educational and cultural differences.

Additionally, another important factor contributing to the increasing prevalence of hypertension in Israel is unhealthy lifestyle habits, such as a diet high in salt and saturated fat, sedentary behavior, and smoking. These lifestyle factors can increase the risk of hypertension, and are becoming increasingly common in Israel, particularly among younger generations. Obesity, a major risk factor for hypertension, is also on the rise in Israel. According to recent data, the prevalence of obesity among adults in Israel has increased significantly over the past decade, with around 27% of adults now classified as obese. In response to the growing prevalence of hypertension in Israel, healthcare providers are emphasizing the importance of early detection and treatment. Lifestyle changes, such as diet and exercise, can help manage hypertension, but many people also require medications to lower their blood pressure. Ongoing research into new and more effective treatments for hypertension is also essential in combating the growing prevalence of this condition in Israel. This, in turn, increased the demand for Israel anti-hypertensive drugs market in the forecast period.

Advancements in Drug Development

In April 2021, Radnor Biopharma developed a hormone targeting treatment for hypertension. The factors such as expiration of patent of multiple major drugs along with side effects associated with the hypertension treatment and rise in the availability of other non-pharmacological based therapy, will restrict the growth of the anti-hypertensive drugs market. For Instance, In December 2021, AbbVie, the parent company of Allergan, lost the patent of its anti-hypertensive drug, Bystolic (Nebivolol). Nebivolol is a beta blocker used to treat high blood pressure and heart failure. These factors propell the growth of Israel anti-hypertensive market.

Additionally, in December 2021, Dr Reddy's Laboratories has launched Valsartan tablets, used for treatment of high blood pressure and heart failure, in the United States market. The Valsartan tablet is the generic therapeutic equivalent of Diovan, approved by the United States Food and Drug Administration (USFDA). Similarly, in November 2021, Otsuka Pharmaceutical Co., Ltd. reported that Novartis Pharma K.K. (Novartis Pharma) has obtained approval in Japan for ENTREST 100 mg and 200 mg Tablets (generic name: sacubitril valsartan sodium hydrate) for the new indication of hypertension. ENTRESTO is classified as a new class called an Angiotensin Receptor Neprilysin Inhibitor (ARNI) with a novel mechanism of action that simultaneously inhibits neprilysin (NEP) and the renin-angiotensin-aldosterone system (RAAS). This approval is Japan's first of an ARNI for the indication of hypertension.

Government Initiatives and Funding

Israel has been collaborating with United Nations to improve the lives of older persons for many years and has worked closely with the United Nations Economic Commission for Europe (UNECE) and its Task Force on Ageing and measuring institutional populations for defining indicators and metrics. Certain other factors that will boost the growth of the Israel anti-hypertensive drugs market include growing initiatives by private and government organizations and rising awareness about hypertension around the around. Few organizations have taken initiatives to conduct a camp and check the blood pressure, making them aware of various aspects of high blood pressure. It certainly adds to the growth of Israel anti-hypertensive market.

The growing awareness of the health risks associated with hypertension in Israel has led to increased efforts to prevent and treat the condition. Public health campaigns, educational programs, and outreach initiatives have been implemented to raise awareness of the importance of managing blood pressure and reducing the risk of hypertension-related health problems. Doctors and other healthcare professionals have increasingly emphasized the importance of monitoring blood pressure and treating hypertension early, to prevent long-term health consequences. As a result, more people are being diagnosed with hypertension and receiving treatment for the condition.

Public health campaigns have also played a role in increasing awareness on the health risks associated with hypertension in Israel. These campaigns aim to educate the public about the importance of healthy lifestyle choices, such as diet and exercise, in preventing hypertension. They also encourage people to get their blood pressure checked regularly and to seek medical treatment if their blood pressure is high. In addition to public health campaigns, educational programs and outreach initiatives have been implemented to raise awareness of hypertension in Israel. These programs focus on educating people about the risk factors for hypertension, the importance of blood pressure monitoring, and the benefits of early intervention and treatment.

The Israel’s Ministry of Health has also taken steps to address the growing prevalence of hypertension by implementing national guidelines for the prevention, diagnosis, and treatment of the condition. These guidelines emphasize the importance of lifestyle modifications, such as reducing salt intake and increasing physical activity, as well as taking medications, when necessary. Therefore, the growing awareness of the health risks associated with hypertension in Israel has led to increased efforts to prevent and treat this condition. The prevalence of hypertension and its associated health risks will continue to decrease in Israel with continued efforts to educate public and these factors propels the growth of Israel anti-hypertensive market.

Download Free Sample Report

Market Segmentation

Israel Anti-Hypertensive Drugs Market can be segmented by therapeutic class, type, distribution channel, and region. By therapeutic class, the market can be segmented into Diuretics, ACE inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others. Based on type, the market can be segmented into Primary Hypertension and Secondary Hypertension. In terms of Distribution Channel, the market can be segmented into Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores.

Market Players

Pfizer Pharmaceuticals Israel Ltd, MERCK SERONO LTD., AstraZeneca Israel Inc, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, Boehringer Ingelheim Israel Ltd., Bristol-Myers Squibb Israel Ltd., Takeda Israel Inc., Teva Israel Ltd., Servier Israel Inc. etc. are some of the leading companies operating in the Israel anti-hypertensive drugs market.

Report Scope:

In this report, Israel Anti-Hypertensive Drugs Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

    ·         Israel Anti-Hypertensive Drugs Market, By Therapeutic Class

o    Diuretics

o    ACE inhibitors

o    Angiotensin Receptor Blockers (ARBs)

o    Calcium Channel Blockers

o    Beta Adrenergic Blockers

o    Renin Inhibitors

o    Vasodilators

o    Others

    ·         Israel Anti-Hypertensive Drugs Market, By Type

o    Primary Hypertension

o    Secondary Hypertension

    ·         Israel Anti-Hypertensive Drugs Market, By Distribution Channel

o    Retail Pharmacy

o    Hospital Pharmacy

o    E-commerce Websites

o    Online Drug Stores

    ·         Israel Anti-Hypertensive Drugs Market, By Region:

o    The Mediterranean coastal plain

o    The Central Hills

o    The Jordan Rift Valley

o    The Negev Desert

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Israel Anti-Hypertensive Drugs Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Israel Anti-Hypertensive Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]